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trastuzumab (11 703 935 €), rituximab (9 153 856 €); in terms of DID: ifosfamid (3,43
(2004) and 6,3 (2009)), gemcitabine (4,88 (2004) and 4,66 (2009)), fluorouracil (3,14
(2004) and 2,85 (2009)). CONCLUSIONS: Financial expenditures for antineoplastic
agents are rising due to use of newand expensivemedications,which are supposed
to double within coming years and are expected to decrease one third of cancer
mortality. Senescent population with higner incidence of cancer disease is ex-
pected to slightly increase DID and medicine packages consumption.
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UTILISATION OF DRUGS INVOLVED IN TREATMENT OF STAGE I AND STAGE II
BREAST CANCER IN SLOVAK REPUBLIC
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OBJECTIVES: Breast cancer forms in tissues of thebreast, usually inducts and lobules.
It is themost common type ofwoman‘s cancer in Slovakia (age- standardized rate- 48,
incidence rate - 2016 new cases every year, mortality rate 773 deaths annually ). The
aim of this study was to provide comparable and reliable data of utilisation of stage I
(invasive, up to 2 centimeters, no lymph nodes involved) and stage II (invasive, 2-5
centimeters, lymph nodes might be involved, over 5 centimeters- no lymph nodes
involvement) breast cancer drugs within the period 2004-2009.METHODS: Analysed
datawere abstracted fromSlovak Institute forDrugControl,which collects them from
wholesalers. Data were studied in accordance with Daily Defined Dose (DDD, with
exception of trastuzumab) and in financial units (€). RESULTS: The consumption of
drugs used in stage I and II breast cancer had increasing trend in terms of financial
burdens between 2004 and 2009 with anastrozole ( from 1 378 317 € to 1 888 478 €),,
doxorubicine (from776 400 € to 1 354 072 €),methotrexate ( from138 954 € to 650 993 €)
and trastuzumab (from 359 797 € to 11 703 935 €) decreasing trend with tamoxifen (
from261417 € to 159064 €) nadalternating trendwith cyclofosfamide ( 206156 € (2004),
223 867 € (2006), 207 042 € (2009)), epirubicine ( 238 125 € (2004), 908 690 € (2007), 629 757
€ (2009)) and fluorouracil ( 444 627 € (2004), 455 578 € (2006), 339 232 € (2009)). Highest
consumption in terms of DDD showed fluorouracil (3,24 DID (DDD/1000 inhabitants/
day) in 2006, 2007, 2008) andhighest increase ofDDDanastrazole ( 0,14DID (2004), 0,46
DID (2009)). CONCLUSIONS: Optimal treatment of breast cancer requires different
therapies. Trastuzumab is well established on Slovak market due to good reasults in
early stage treatment with few recidives. Consumption of tamoxifen and anastrozole
will be influenced by exemestane.
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NILOTINIB AND HIGH DOSES OF IMATINIB
Orozco Giraldo JJ1, Valencia JE2, Garrido Lecca S3, Aiello EC4
1CES University, Medellin, Antioquia, Colombia, 2Bristol-Myers Squibb, Bogota, Colombia,
3Bristol-Myers Squibb, Lima, Peru, 4Bristol-Myers Squibb, Buenos Aires, Argentina
OBJECTIVES: Within the framework of Chronic Myelogenous Leukaemia (CML)
treatment in Peru, and based on a previously performed economic evaluation, we
compared the costs and cost-effectiveness ratio of using 100mg/day and 140 mg/
day doses of Dasatinibwith the use of 800mg/day doses of Nilotinib or an increased
dose of Imatinib (800mg/day), for each phase of the disease, in patients who devel-
oped resistance to habitual doses of Imatinib. METHODS: A Markov model was
used for this economic evaluation, which considered a cohort of 10.000 CML pa-
tients in its three phases (chronic, accelerated and blast phase), a lifetime horizon
and a 3.5 % discount rate for costs and benefits. Model results included the costs of
each treatment alternative with Dasatinib, Nilotinib or Imatinib, and Quality Ad-
justed Life Years (QALYs) gained. Costs were measured in Peruvian SOLES of year
2010. RESULTS: In the chronic phase of the disease, dasatinib 100 mg/day yielded
the highest amount of QALYs with 6,62 and the lowest cost-effectiveness ratio. In
the accelerated phase, Dasatinib 140mg/day also showed the lowest cost-effective-
ness compared to Nilotinib and Imatinib. In the blast phase, dasatinib showed
lower cost-effectiveness ratio than imatinib.CONCLUSIONS:Dasatinib 100mg/day
showed the lowest cost-effectiveness ratios than doses of 800 mg/day of Nilotinib
and imatinib 800 mg for the treatment of patients with CML resistant to usual
imatinib doses in the chronic phase, as well as in the accelerated and blast phases.
Although there was an overall cost increase, especially due to the cost of Dasatinib
in 140 mg/day doses, this fact was explained by the increase in life years gained
and, consequently, the use of medical resources and drugs.
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OBJECTIVES: To determine the burden of bone metastases and health resource
utilisation (HRU) associated with skeletal-related events (SREs) in patients with
advanced cancer. METHODS: This observational study assessed HRU associated
with SREs (defined as spinal cord compression [SCC], surgery to bone [SB], patho-
logic fracture [PF] or radiation to bone [RB]). Patients with breast, lung or prostate
cancer metastatic to bone or multiple myeloma and life expectancy 6 months
were enrolled in centres in Germany, Italy, Spain, UK, Canada and USA after expe-
riencing a SRE. We report here the European HRU data on hospitalisation, which
were collected retrospectively for the 90 days prior to enrolment and prospectively
for approximately 18-21months. RESULTS: 631 eligible patientswith a total of 1282
SREswere enrolled across 95 European sites: 223 (35.3%) had a primary diagnosis of
breast cancer, 135 (21.4%) lung cancer, 120 (19%) prostate cancer and 153 (24.3%)
multiple myeloma. Across all tumour types, for Germany, Italy, Spain and UK,
respectively, the mean number of hospitalisations per SCC (n  91) was 0.85, 0.69,
0.53 and 1.06 with a mean length of stay (per SRE with  1 hospitalisation) of 25.6,
41.1, 34.3 and 27.7 days. For SB (n  137) mean number of hospitalisations per SRE
was 0.90, 0.76, 0.83 and 0.75 withmean stays of 19.4, 19.8, 8.4 and 10.0 days, respec-
tively. For PF (n 254),mean number of hospitalisations per SREwas 0.42, 0.49, 0.49
and 0.39 with mean stays of 18.7, 22.4, 20.2 and 20.7 days, respectively. Mean
number of hospitalisations per RB (n 692) were 0.19, 0.15, 0.16 and 0.07withmean
stays of 17.9, 16.6, 21.9 and 10.4 days respectively.CONCLUSIONS: Each SRE leads to
considerable hospitalisation, which varies by SRE type and country.
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USE OF SUBSTANCE ABUSE AMONG RESIDENTS OF KARACHI: REASONS AND
COST OF USING SUBSTANCES
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Aga Khan University, Karachi, Sindh, Pakistan
OBJECTIVES: Use of substances (pan, chaalia, ghutka, niswar) is associated with
serious health risks. In Pakistanmost people use substances from early years of life
which keeps them on risk of short life span. It is important to understand the cost
implication and provide knowledge about the effects of these substances. The aim
of this studywas to estimate the costs of using these substances and to understand
the reasons for using substances. METHODS: This was a cross-sectional study
conducted in two residential colonies in Karachi, Pakistan during 2008 and 2009.
Pre-coded structured questionnaire was administered to collect the data on socio
demographics, costs, reasons for use of substances and use of substances per day.
The data was analyzed on SPSS version 18.0. Possible measures were taken to
ensure the confidentiality of all participants. RESULTS: From 124 randomly se-
lected residents, 107 (86%) agreed to respond. All the selected participants were
between the ages 10–71 years (meansd age 36.216.4). Of the total, about one-
fifth of the users were females. Daily use of substances was significantly higher
among males (p0.001). Further, the use was higher among adolescents than
adults (p0.001) and interestingly less educated consumed less thanhigh educated
(P0.06). Males are spending significantly higher on substances; Rs. 3711.5/day
[Rs.930 or (US$13)/month] compared to females. Overall, 41% of the cost is spent on
cigarettes followed by 27% and 23% on local and branded ghutka respectively. The
main reasons for using substances were peer pressure, easy availability of sub-
stances, stress, liking of taste and to treat toothache. CONCLUSIONS: This study
concluded that use of substances is higher among youngmales and they are spend-
ing a lot on them. To prevent this population, regular awareness campaignsmay be
held at community and school level so that, continuous re-enforcement make
them to quit from using any kind of substances.
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OBJECTIVES:Worldwide, prices for cancer drugs have been under downward pres-
sure where several governments havemandated price cuts of branded products. A
better alternative tomandated price cuts would be the estimation of a launch price
based on drug performance, cost effectiveness and a county’s ability to pay. We
developed a global pricing index for new drugs that encompasses all of these attri-
butes in patients with metastatic colorectal cancer (mCRC). METHODS: A phar-
macoeconomic model was developed to simulate clinical outcomes in mCRC pa-
tients receiving chemotherapy with the addition of a “new drug” that improves
survival by 1.4, 3 and 6 months. Cost and health state utility data were obtained
from cancer centers and oncology nurses (n112) in Canada, Spain, India, South
Africa and Malaysia. A price per dose was estimated for each survival increment
using a target value threshold of three times the per capita GDP for each country, as
recommended by the World Health Organization (WHO). Multivariable analysis
was then used to develop the pricing index, which considers survival benefit, per
capita GDP and income dispersion as measured by the Gini coefficient as predictor
variables. RESULTS: Higher survival benefits were associated with elevated drug
prices, especially in wealthier countries such as Canada. For Argentina with a per
capita GDP of $15,000 and a Gini coefficient of 51, the pricing index estimated that
for a drugwhich provides a 4month survival benefit inmCRC, the value based price
would be $U.S.630 per dose. In contrast, the same drug in a wealthier country like
Norway could command a price of $U.S.2,775. CONCLUSIONS: The application of
this index to estimate a price based on cost effectiveness would be a good starting
point for opening dialogue between the key stakeholders and a better alternative to
governments’ mandated price cuts.
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OBJECTIVES: Imatinib is considered standard of care for 1st line treatment of
chronic myeloid leukemia (CML) in Brazil. Long-term treatment effectiveness,
however, is jeopardized by questionable adherence among patients receiving
imatinib. The goal of this study is to document the adherence of CML patients to
imatinib and the impact of these adherence levels on long-term prognosis.
METHODS: A longitudinal cohort analysis was performed using SIA/DATASUS
data from January 2008 through Jun 2010. Inclusion criteria included patients 
18 years old; diagnosed with CML (ICD10 92.1) in Chronic Phase; beginning 1st
line treatment with imatinib from January 1, 2008 to December 31, 2008; and a
minimum follow-up period of 6 months. Adherence of all patients that met
inclusion criteria was calculated based on medication possession ratio (MPR)
over a 15-month period. Patients were categorized as adherent (MPR  0.9) or
non-adherent (MPR  0.9). Using uni and multivariate logistic regression we
analyzed the following covariates: adherence, age, gender, region of country
and other comorbidities for their influence on progression rates. RESULTS: In
total, 386 patients, 56% males and mean (SD) age 48 (15) years, were included in
the study. There were 210 (54%) patients calculated as being adherent (MPR 
0.9). At the end of the 24-months of follow-up, 20% patients from the non-
adherent group had progressed, versus 10% in the adherent group (log-rank
p0,02). Patients from North, South and Southeast regions of Brazil had signif-
icantly higher adherence as compared with those from Northeast or Center-
west. According to the multivariate logistic regression, lower adherence is sig-
nificantly associated with higher progression rates. CONCLUSIONS: Adherence
to imatinib is associated with a better progression-free survival profile, with
statistical significance being observed after a 24-months period. Non-adherence
was observed in 46% of the population studied.
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OBJECTIVES: Given that treatments for advanced breast cancer are palliative
rather than curative, the patient-perceived impact of chemotherapy is a critical
outcome. To date, no studies have estimated the strength of patient preferences for
a comprehensive set of toxicities associated with breast cancer treatments. The
objective of this study was to measure patient preferences for treatment-related
toxicities in advanced breast cancer. METHODS: This was a cross-sectional Web-
based survey of women with stage I through IV breast cancer who were recruited
through web forums and newspaper ads. Using the standard gamble approach,
each participant valued her own current health state in the absence of side effects
and nine health states describing that current health state plus each of nine grade
III/IV toxicities. Toxicity disutilities were calculated by subtracting the utility for
current health from that for current health plus the toxicity. RESULTS: Of the 103
patients who completed the web survey, 21 had to be excluded given irrational
responses. The mean ‘current health’ utility for the sample was 0.837. Patients
assigned higher utilities to their current health state than to the toxicity states.
Alopecia received the highest utility (mean0.79; disutility  4.6) of all the side
effects, and diarrhea received the lowest (mean0.69; disutility  14.7). Patterns
were similar across disease stages, although patients with more advanced disease
(stage III or IV) generally assigned lower utilities (greater disutilities) to the various
toxicities. For several side effects (alopecia, nausea, vomiting, fatigue, mucositis,
and diarrhea), patients who had experience with the side effect reported higher
utility values compared to those who had not experienced the side effect.
CONCLUSIONS: To our knowledge, this study was the first to report strength of
preferences for toxicities associated with advanced breast cancer treatments. The
utilities obtained in this studymay be used in future cost-effectiveness evaluations
of breast cancer therapies.
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OBJECTIVES: Peoples’ beliefs towards health and illness play an important role in
health seeking behavior. Cancer patients’ beliefs regarding cancer have been re-
ported to be important factors affecting screening and treatment seeking behavior.
This study was aimed to evaluate cancer patients’ beliefs about cancer and its
causes. METHODS: A qualitative research approach was adapted. After obtaining
institutional ethical approval, patients with different types and stages of cancer
from the three major ethnic groups in Malaysia were purposively selected to par-
ticipate in the interview. Twenty patients whom had consented were interviewed
using a semi-structured interview guide. After conducting 18 interviews the satu-
ration point was reached and nomore themes were emerged from the subsequent
interviews. All interviews were audiotaped, transcribed verbatim and translated
into English for thematic content analysis. RESULTS: The emergent themes were
as follows: unknown reasons, internal factors, environmental perceptions, and
spiritual attributions. In this preliminary investigation cancer patients described
cancer as a disease present in every human being and itmay become visible during
the course of life. Genetic predisposition, female gender and hematological factors
were reported to be some of the internal factors. Unhealthy life style habits such as
smoking, high consumption of red meat, and pesticides in foods were some of the
environmental factors that were described. Among those who claimed to have
healthy habits prior to the illness, there was a rejection of the notion that un-
healthy life style was a cause. A strong spiritual connection was found as many
patients described their cancer diagnosis as ‘God’s will.’ CONCLUSIONS: This ex-
ploratory investigation suggests that cancer patients’ understanding about cancer
is complex in nature. The findings may help health care providers remove myths
about cancer and reassure patients during the treatment decisionmaking process.
It may also help in improving patients’ compliance towards the proven cancer
therapies.
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OBJECTIVES: To assess patients’ knowledge of chronic myeloid leukemia (CML)
treatment response categorizations and to evaluate health-related quality-of-life
(HRQOL) outcomes and treatment satisfaction among CML patients achieving dif-
ferent levels of responses. METHODS: CML patients were invited to complete an
on-line survey that assessed their knowledge of different CML treatment-response
categorizations. Data on HRQOL outcomes and treatment satisfaction were also
collected. Chi-square and Fisher’s test were used for statistical comparisons.
RESULTS: 123 patients obtained through the ACOR database completed the survey.
The mean age of respondents was 63 years, 48.8% were male, and 95.9% had some
level of college experience. Over 90% were familiar with the different levels of CML
treatment responses, with 96.8% self-reporting a current hematologic response,
70.7% a current cytogenetic response, and 68.3% a molecular response. However,
71.5% felt CML patients needmore information on the types of responses, with the
desire for information to come from their physicians (66.7%) rather than fromother
staff (28.5%) or pamphlets (23.6%). Achieving a molecular response (as opposed to
hematologic/cytogenetic responses) generated the greatest satisfaction with their
physician (78.6%), medication (86.6%), outlook on life (85.7%), and day-to-day func-
tioning (85.7%). The percentage of patients rating their own health as excellent/
very good was 43.1% among those with a molecular response and 41.7% with a
cytogenetic response. However, 21.9% of all subjects rated their health as fair/poor.
CONCLUSIONS: Achievement of a molecular response was associated with a
higher satisfaction with a patient’s physician, medication, and outlook on life, as
well as an overall improvement in self-reported health ratings. Even in this highly
educated ACOR population, a need for physician-directed information about vari-
ous response criteria and counseling about the value of obtaining a molecular
response is desired.
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OBJECTIVES: To evaluate and compare the preferences for targeted therapy for
metastatic renal cell carcinoma in cancer patients, patients’ family members and
medical experts. METHODS: Using discrete choice experiment, survey questions
were constructed on the basis of six attributes of efficacy, adverse events and
administration. We designed two kinds of scenario sets as first-line therapy and
therapy for poor prognosis. A total of 485 individuals were completed question-
naire: 140 cancer patients, 60 patients’ familymembers and 285medical experts(39
oncology doctors, 34 oncology nurses, 133 nurses and 79 pharmacists).RESULTS: In
first-line therapy and therapy for poor prognosis, all six attributes in studies were
statistically significant so they were important for choices. In first-line therapy
coefficients of six attributes in patients and medical experts were all statistically
significant but not progression free survival(PFS) in patients’ family members. Be-
tween patients and doctors, PFS, hand-foot skin reaction(HFSR) and administration
were statistically significantly different. Between patients and nurses, the coeffi-
cients of bonemarrow suppression, HFSR, gastrointestinal perforation and admin-
istration were significantly different. In therapy for poor prognosis, six attributes
were statistically significant in patients but not administration in patients’ family
members, not HFSR, interstitial pneumonitis in doctors. Between patients and
doctors, coefficients of PFS, HFSR, asthenia and interstitial pneumonitis were dif-
ferent significantly. Between patients and nurses, five attributes were significantly
different except HFSR.CONCLUSIONS: Efficacy, adverse events and administration
were all important for preference in respondents. Comparisons of coefficients be-
tween subgroups represented different preferences of those groups. Medical ex-
perts especially doctors showed quite different preferences from patients and pa-
tients’ family members. Doctors considered efficacy more important than adverse
event so they favored the more effective and orally administered drug even if the
drug had adverse events more frequently. But patients and patients’ family mem-
bers showed reluctant attitudes about adverse events.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common cancers world-
wide. major treatment advances, however, have changed the assumptions about
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